Joint project
OPENCORONA - Rapid therapy development through Open nCoronavirus Vaccine Platform
Funder: European Union
Period: 2020-2022
URI: https://cordis.europa.eu/project/id/101003666/de
Abstract:
A DNA vaccine platform against SARS-CoV-2
Accumulating genetic evidence on the new SARS-CoV-2 virus shows that its envelope and receptor binding domain only share 75 % homology with other human coronaviruses. This indicates that existing immunotherapies and vaccine candidates against other coronaviruses will probably not work against SARS-CoV-2. To generate and select the most potent candidates that protect against SARS-CoV-2 infection, the EU-funded OPENCORONA project will use a DNA vaccine platform. The most promising leads will initially be validated in animal models of coronavirus infection and then tested in a phase I clinical trial for safety in healthy volunteers.
A DNA vaccine platform against SARS-CoV-2
Accumulating genetic evidence on the new SARS-CoV-2 virus shows that its envelope and receptor binding domain only share 75 % homology with other human coronaviruses. This indicates that existing immunotherapies and vaccine candidates against other coronaviruses will probably not work against SARS-CoV-2. To generate and select the most potent candidates that protect against SARS-CoV-2 infection, the EU-funded OPENCORONA project will use a DNA vaccine platform. The most promising leads will initially be validated in animal models of coronavirus infection and then tested in a phase I clinical trial for safety in healthy volunteers.
Coordinating organisation / Consortium Leader
- Karolinska Institutet
Cooperation partners with funding
1 of 2
- Adlego Biomedical AB
- IGEA S.p.A.
- NorthX Biologics
- Public Health Agency of Sweden - Folkhalsomyndigheten
- Stockholm County Council
